|
Interagency Group for Development of Lung Infection Models for P. aeruginosa and A.baumannii
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, CDC, FDA
|
NIAID
|
This interagency working group meets quarterly to discuss the development of various lung infection animal models.
|
|
Interagency Group on Alzheimer& Disease and Related Dementias for implementation of the National Alzheimer& Project Act
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, AoA, ASPE, ACF, IHS, OASH, SAMHSA
|
NIA
|
This interagency group was established by Department of Health and Human Services (HHS) in response to the Congressional directive to address Alzheimer disease. The group works to carry out the National Alzheimer’s Project Act’s charges to coordinate research and services across agencies, accelerate the development of AD/ADRD treatments, improve early diagnosis and coordination of care, reduce ethnic and racial disparities in rates of AD/ADRD, and coordinate with international efforts to fight these conditions.
|
|
Interagency Modeling and Analysis Group (IMAG)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA
|
NIBIB, CSR, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NLM, OD/DPCPSI, OD/DPCPSI/OBSSR
|
IMAG is comprised of program directors from over 10 government agencies including the National Institutes of Health (NIH), the National Science Foundation (NSF), Department of Energy (DOE), Department of Defense (DOD), the Department of Agriculture (USDA), the National Aeronautics and Space Administration (NASA), the Department of Veterans Administration (VA), the Food and Drug Administration (FDA), and the Intelligence Advanced Research Projects Activity (IARPA). The purpose of IMAG is to bring together program staff who have a shared interest in supporting modeling and analysis methods in biomedical, biological, and behavioral systems. IMAG has promoted and supported a wide variety of modeling, notably multi-scale modeling (MSM) through agency-specific funding opportunity announcements. IMAG also holds consortium meetings annually, however in 2021 a consortium meeting was not held, due to the COVID-19 pandemic.Instead, IMAG and the MSM remained active through individual working group and special interest group activities. A new Multiscale Modeling and Viral Pandemics working group was created, hosting over 30 subgroups, promoting weekly webinars throughout the year that involved participants from several IMAG agencies, including NIH, CDC, FDA, NSF and DOD and the associated extramural communities. Additionally, a new collaboration was formed between NIH, CDC, DARPA, NASA with the MSM Committee on Credible Practice of Modeling ; Simulation in Healthcare (CPMS, which includes NIH and FDA) to evaluate the credibility of the processes used for developing the COVID-19 pandemic models. The credible practices were evaluated in relation to this article, which was published after eight years of work between the CPMS and the IMAG and the MSM Consortium, https://www.imagwiki.nibib.nih.gov/resources/publications/credible-prac….
|
|
Interagency Morphine Milligram Equivalent (MME) Workgroup
|
Committee, Work group, Advisory group, or Task Force
|
FDA, CDC
|
NIDA
|
The Interagency Morphine Milligram Equivalent (MME) Workgroup is a transagency workgroup that was established in 2022 to identify research priorities and set recommendations around MME calculations for research and clinical practice.
|
|
Interagency Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NINDS, NIAID
|
The Interagency ME/CFS Working Group consists of multiple government agencies and patient ME/CFS patient advocacy organizations interested in research and care issues related to ME/CFS. The working group was established to help coordinate ME/CFS-related efforts across the federal agencies to enhance research efforts, improve treatment options and patient outcomes, promote public outreach, and strengthen workforce development. The working group, which is co-led by NINDS and CDC, met for the first time in August 2020, and will continue to meet regularly to provide updates, discuss issues relevant to ME/CFS research, and identify and foster communication and collaboration across the federal agencies and with ME/CFS stakeholders.
|
|
Interagency Oncology Task Force Fellowship: Track 4
|
Training Initiative
|
FDA
|
NCI
|
This fellowship will provide training in cancer prevention (e.g., chemoprevention, vaccination, and early detection). Individuals will be trained in the drug, biologic, or device development and approval processes and their application to study populations (including healthy subjects) to facilitate the movement of novel approaches from the bench to the community. Combining training in public health, cancer prevention research, and research-related regulatory overview will allow individuals to develop expertise across these disciplines.
|
|
Interagency Pain Research Coordinating Committee (IPRCC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, SAMHSA
|
NINDS, NCCIH, NIDA, NIDCR, NINR, NIA
|
The Interagency Pain Research Coordinating Committee is an Affordable Care Act-mandated committee to coordinate pain research activities across the government.
|
|
Interagency Pediatric Surge Working Group
|
Committee, Work group, Advisory group, or Task Force
|
NIH, CDC, HRSA, ASPR
|
NICHD
|
The interagency working group meets weekly to discuss pressing surges and opportunities as it relates to addressing pediatric healthcare capacity, delivery and science.
|
|
Interagency Rehabilitation and Disability Research Portfolio (IRAD)
|
Resource Development
|
ACL, CDC
|
NICHD
|
IRAD is a searchable database of government funded research projects in the areas of disaiblity, independent living and rehabilitation research. The purpose of IRAD is to provide a publicly available resource that enables analysis of the federal research portfolio in disability, independent living, and rehabilitation research. This will aid in collaboration and coordination of research activities across federal agencies, as well as increase transparency and visibility for the public and legislative stakeholders.
|
|
Interagency Select Agent Review Group (ISARG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, OS
|
NIAID, OD/OM/OB, OD/OSP
|
The Interagency Select Agent Review Group (ISARG), composed of members from the Centers for Disease Control and Prevention (CDC), the Department of Justice, the Department of State, the National Institutes of Health Office of the Director (NIH-OD) and the Biomedical Advanced Research and Development Authority (BARDA), advises the National Institute of Allergy and Infectious Diseases (NIAID) on whether facilities and procedures at NIAID-funded foreign research sites are comparable to those required by the Select Agent Regulations for domestic institutions before Select Agent work at the foreign site may proceed.
|